US FDA extends review for Liquidia’s inhaled blood pressure drug

The U.S. Food and Drug Administration extended the review of Liquidia Corp's drug for the treatment of a progressive blood vessel disorder related to a lung condition, the company said on Thursday. The FDA did not give a new deadline, nor did it request for any additional clinical data to support the marketing application, the company said.